Vaccination program to protect five million 11-to 13-year-old girls against the human papilloma virus (HPV), which can cause cervical cancer has started in Brazil.
Pap smear and Cervical Cancer Screening
Pap smear is the most common test used in screening cervical cancer caused by an infection with human papilloma virus. Pap smear should be repeated every 1 to 3 years till the age of 65 years.
Pap smear is the most common test used in screening cervical cancer caused by an infection with human papilloma virus. Pap smear should be repeated every 1 to 3 years till the age of 65 years.
The first year of the program will see 15 million doses -- three per child -- administered. The government hopes to reach at least 80 percent of Brazil's 5.2 million girls in the targeted age group.
The World Health Organization says cervical cancer is the second most common form of the disease in women worldwide, each year bringing 250,000 deaths and 500,000 new cases.
Research: HPV-Positive OPSCC Patients Nearly Twice as Likely to Survive as HPV-Negative Patients
Research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium highlights a retrospective analysis of oropharyngeal cancer patients with recurrence of disease.
Research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium highlights a retrospective analysis of oropharyngeal cancer patients with recurrence of disease.
Quiz on Cervical Cancer
Cervical cancer remains a common cancer in women of the developing world despite a test available for early diagnosis and a vaccine to prevent it. Here’s a quiz to test your knowledge on cervical cancer.
Cervical cancer remains a common cancer in women of the developing world despite a test available for early diagnosis and a vaccine to prevent it. Here’s a quiz to test your knowledge on cervical cancer.
Targeted Drug Proves Effective for Cervical Cancer
Brazilian researchers have found that drug erlotinib in combination with cisplatin-based chemoradiation therapy (CRT) can prove very effective in treatment of cervical cancer.
Brazilian researchers have found that drug erlotinib in combination with cisplatin-based chemoradiation therapy (CRT) can prove very effective in treatment of cervical cancer.
